Lanvis

Tioguanine, the active ingredient in Lanvis, is a thiopurine presented as an oral tablet for oral use. It is employed as an immunosuppressant in the treatment of certain leukemias and inflammatory bowel disease, targeting rapidly dividing cells in affected patients. GNH USA supplies Lanvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lanvis (tioguanine) is used in diseases where abnormal proliferation of lymphoid or myeloid cells occurs, or where immune modulation is required. Acute lymphoblastic leukemia: helps achieve remission by inhibiting malignant lymphoblast proliferation. Chronic myeloid leukemia: contributes to disease control when used in combination regimens. Inflammatory bowel disease: reduces inflammatory activity and maintains remission in ulcerative colitis or Crohn's disease.

Adverse reactions may occur with tioguanine therapy and should be monitored.

Common Side Effects: - Nausea or vomiting - Diarrhoea - Mild rash or skin irritation - Transient elevation of liver enzymes - Decreased white blood cell count (leukopenia)

Serious or Rare Side Effects: - Severe bone‑marrow suppression leading to pancytopenia - Life‑threatening infections due to immunosuppression - Hepatic toxicity or jaundice - Acute pancreatitis - Secondary malignancies such as lymphomas - Severe hypersensitivity reactions including Stevens‑Johnson syndrome

Tioguanine requires careful monitoring and patient education before and during therapy. Monitor blood counts regularly: detect early bone‑marrow suppression. Assess liver function: watch for hepatotoxicity. Avoid use in patients with known hypersensitivity to thiopurines. Use caution in renal impairment: dose adjustment may be needed. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Tioguanine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Azathioprine: additive immunosuppression increases risk of severe cytopenias. - Allopurinol: can markedly raise tioguanine levels, leading to toxicity. - Warfarin: may enhance anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - Methotrexate: combined myelosuppression requires frequent blood‑count checks. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation. - Trimethoprim‑sulfamethoxazole: can potentiate bone‑marrow suppression.